Simvastatin (Zocor)
(Synonyms: 辛伐他汀; MK 733) 目录号 : GC10585An HMG-CoA reductase inhibitor
Cas No.:79902-63-9
Sample solution is provided at 25 µL, 10mM.
Simvastatin (SIM), a lactone, is white, crystalline, nonhygroscopic and powdery, practically insoluble in water (30 mcg/ml), and 0.1 (N) HCl (60 mcg/ml). Its precursor is a fermentation product of Aspergillus terreus. It is used for treating coronary heart disease, hyperlipidemia, hypercholesterolemia, atherosclerosis and stroke [1] [2]. SIM is biologically inactive. Oral ingestion hydrolyzed it into the β-hydroxyacid form which is an inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase [2]. In human lung microvascular endothelial cells, it increased the amount of endothelial nitric oxide synthase mRNA [3]. Simvastatin had anti-cancer properties [1]. Its IC50 to inhibit P-glycoprotein is 9 μM [4].
HMG CoA reductase catalyses an early rate-limiting step in the biosynthesis of cholesterol [2].
In both cell lines HepG2 and Huh7, both doses of simvastatin (32 and 64 μM) had a significant inhibitory effect on tumor cell growth as compared to controls (p<0.05). This effect was time-dependent, a simvastatin pre-treatment for 48 h or 72 h significantly reduced cell growth as compared to 24 h pre-incubation (p<0.05). Simvastatin treatment for 48 or 72 h made HepG2 cells exhibit downregulation of CDK1, CDK2, CDK4 and cyclins D1 and E as compared to control tumor cells. Simvastatin treatment for 24, 48 and 72 h made relative expression of cyclin-dependent kinase inhibitors p19 and p27 enhance as compared to control tumor cells [1].
In patients with polygenic hypercholesterolemia and allocated to diet plus 20 mg/day simvastatin for 8 weeks, total cholesterol (-27%), low density lipoproteincholesterol (-33%), and monocyte expression of TNF (-49%) and IL-1( (-35%) significantly decreased (p<0.02) [5].
References:
[1]. Borna Relja, Frank Meder, Kerstin Wilhelm, et al. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. International Journal of Molecular Medicine, 2010, 26:735-741.
[2]. Dipika Mandal, Probir Kumar Ojha, Bankim Chandra Nandy, et al. Effect of Carriers on Solid Dispersions of Simvastatin (Sim): Physico-Chemical Characterizations and Dissolution Studies. Der Pharmacia Lettre, 2010, 2(4):47-56.
[3]. Ji-Hyun Lee, Dong-Soon Lee, Eun-Kyung Kim, et al. Simvastatin Inhibits Cigarette Smoking–induced Emphysema and Pulmonary Hypertension in Rat Lungs. American Journal of Respiratory and Critical Care Medicine, 2005, 172: 987-993.
[4]. C. Bradley Hare, Mai P. Vu, Carl Grunfeld, et al. Simvastatin-Nelfinavir Interaction Implicated in Rhabdomyolysis and Death. Clinical Infectious Diseases, 2002, 35:e111–2.
[5]. Domenico Ferro, Sandro Parrotto, Stefania Basili, et al. Simvastatin Inhibits the Monocyte Expression of Proinflammatory Cytokines in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2000, 36(2): 427–431.
Cell experiment [1]: | |
Cell lines |
Mouse L-M cells (fibroblast), rat H4IIE cells (liver) and human Hep G2 cells (liver) |
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition |
13.3, 15.6 or 19.3 nM |
Applications |
In mouse L-M cells (fibroblast), rat H4IIE cells (liver) and human Hep G2 cells (liver), Simvastatin inhibited cholesterol synthesis with the IC50 values of 19.3 nM, 13.3 nM and 15.6 nM, respectively. |
Animal experiment [1]: | |
Animal models |
Dogs |
Dosage form |
50 mg/kg/d; p.o.; q.d., for 1 month |
Applications |
Compared with L654,969 group, Simvastatin group showed a much lower serum cholesterol concentration. However, Simvastatin and Lovastatin showed equivalent cholesterol-lowering effects. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs. 1988;36 Suppl 3:72-82. |
Cas No. | 79902-63-9 | SDF | |
别名 | 辛伐他汀; MK 733 | ||
化学名 | [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate | ||
Canonical SMILES | CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C | ||
分子式 | C25H38O5 | 分子量 | 418.6 |
溶解度 | ≥ 20.95mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3889 mL | 11.9446 mL | 23.8892 mL |
5 mM | 0.4778 mL | 2.3889 mL | 4.7778 mL |
10 mM | 0.2389 mL | 1.1945 mL | 2.3889 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet